NCT00556296View on ClinicalTrials.gov

Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD

PHASE3CompletedINTERVENTIONAL
Enrollment

297

Participants

Timeline

Start Date

October 31, 2004

Study Completion Date

September 30, 2005

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

NRP104

NRP104 30mg capsule once daily in a.m.

DRUG

NRP104

NRP104 50mg capsule once daily in a.m.

DRUG

NRp104

NRP104 70mg capsule once daily in a.m.

DRUG

Placebo

Placebo

Sponsors

Collaborators (1)

Shire
All Listed Sponsors
collaborator

Shire

INDUSTRY

lead

New River Pharmaceuticals

INDUSTRY